Positive preliminary results have been reported from the open-label, multicenter phase IIa PEP005-007 clinical trial of PEP-005 (3-angeloylingenol), a patient-applied topical gel for the treatment of actinic keratosis (AK), to determine the optimal tolerated treatment regimen and evaluate the safety and efficacy of the product when applied to a 25 square centimeter area of skin on either the face or the face and scalp for the treatment of AK. The trial evaluated formulation strengths from 0.0025% to 0.025% at two and three consecutive day dosing regimens. The trial established the maximum tolerated dose (MTD) at 0.025% applied daily for two consecutive days. The drug suggested a favorable safety profile and was ...